Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Adefovir Dipivoxil Action Pathway
Homo sapiens
Drug Action Pathway
Created: 2013-08-22
Last Updated: 2019-08-16
Adefovir dipivoxil is an ester prodrug of adefovir, a nucleotide analogue used in the treatment of chronic hepatitis B. Adefovir dipivoxil is taken up into the liver cell and is cleaved into adefovir by intracellular esterases. Adefovir is subsequently phosphorylated first by adenylate kinases and then by nucleoside diphosphate kinases into adefovir diphosphate. Adefovir diphosphate is an analogue of deoxyadenosine triphosphate (dATP) and competes with dATP for binding to the viral DNA polymerase and subsequent incorporation into the growing DNA strand. Once incorporated into the DNA, adefovir causes chain termination, thus preventing viral replication.
References
Adefovir Dipivoxil Pathway References
Dando T, Plosker G: Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs. 2003;63(20):2215-34.
Pubmed: 14498759
Hepsera. (2009). e-CPS (online version of Compendium of Pharmaceuticals and Specialties). Retrieved December 16, 2009.
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Settings